66 results on '"M. Mittaine"'
Search Results
2. Pediatrician intervention impacts parental smoking in cystic fibrosis, diabetes, and bronchiolitis
- Author
-
Geraldine Labouret, Marine Michelet, M. Mittaine, Amélie Arrouy, Carole Morin, Léa Roditis, Maxime Lafont, and Audrey Rabeau
- Subjects
Parents ,Pulmonary and Respiratory Medicine ,Pediatrics ,medicine.medical_specialty ,Cystic Fibrosis ,medicine.medical_treatment ,Cystic fibrosis ,Quit smoking ,03 medical and health sciences ,0302 clinical medicine ,030225 pediatrics ,Diabetes mellitus ,Intervention (counseling) ,Diabetes Mellitus ,medicine ,Humans ,Pediatricians ,Child ,business.industry ,Smoking ,Smoking cessation intervention ,Infant ,medicine.disease ,Smoking cessation advice ,030228 respiratory system ,Bronchiolitis ,Pediatrics, Perinatology and Child Health ,Smoking cessation ,Tobacco Smoke Pollution ,business - Abstract
Background Child exposure to cigarette smoke is harmful. It should be reduced through parental smoking cessation interventions. The aim of our study was to determine the impact of simple advice provided by the pediatrician on the smoking habits of parents of children with cystic fibrosis (CF), diabetes mellitus (DM) and infants hospitalized for bronchiolitis. Methods Parents were interviewed on their smoking habits. Smoking cessation advice was provided by the pediatrician. A new smoking habits assessment was done at three months by phone interviews. Results Two hundred and sixty parents were interviewed (91 in the CF group, 136 in the DM group and 33 in the bronchiolitis group). Seventy parents were active smokers: 33% of parents of children with CF, 23.5% of parents of children with DM and 24.2 % for those with infants hospitalized for bronchiolitis (p = 0.42). In the CF group, smoking cessation had been significantly more frequently discussed with the medical team previously. Sixty-seven smoking parents (95.7%) answered the 3-month assessment: 29.8% reported having started a smoking cessation process; 10.4% had quit smoking. The quitting rate was significantly higher in the groups of patients followed for a respiratory disorder (37.5% for bronchiolitis, 15% for CF versus 0% for DM, p= 0.005). Conclusion This study shows the important role that information and simple advice from pediatricians can have in initiating smoking cessation in parents of patients followed in specialized clinics or who are hospitalized, with a greater efficiency in parents of patients suffering from lung disorders. This article is protected by copyright. All rights reserved.
- Published
- 2021
- Full Text
- View/download PDF
3. Scanner thoracique chez l’enfant atteint de mucoviscidose : intérêt d’un protocole en expiration séquentielle pour réduire la dose d’irradiation
- Author
-
Emmanuel Mas, M. Michelet, C. Baunin, J. Vial, S. Simon, L. Roditis, and M. Mittaine
- Subjects
Pulmonary and Respiratory Medicine ,03 medical and health sciences ,0302 clinical medicine ,030228 respiratory system ,medicine.diagnostic_test ,business.industry ,medicine ,Computed tomography ,030212 general & internal medicine ,Nuclear medicine ,business - Abstract
Resume Introduction Le scanner thoracique est essentiel pour le suivi respiratoire des enfants atteints de mucoviscidose, mais sa repetition expose a la toxicite potentielle des radiations ionisantes. L’objectif de cette etude etait de comparer un protocole scanographique complet (acquisition en inspiration helicoidale puis expiration sequentielle) a un protocole ne comprenant que les coupes expirees, en termes d’analyse d’image et de dose delivree de radiations ionisantes. Methodes Sur une cohorte monocentrique de 57 enfants âges de 5 a 18 ans, 78 examens ont ete scores par deux radio-pediatres sur le protocole complet puis uniquement sur les coupes expirees. Resultats La correlation entre les scores radiologiques globaux obtenus selon les deux protocoles etait tres bonne (r = 0,90 pour les deux radiologues) ainsi que pour les scores de bronchectasies (r = 0,72 et 0,86), impactions mucoides (r = 0,87 et 0,83) et trappage expiratoire (r = 0,96 et 0,92). Les parametres d’irradiation etaient reduits, avec un produit dose longueur (DLP) passant de 103,31 mGy.cm (protocole complet) a 3,06 mGy.cm (protocole expiration seule) (p Conclusion Afin d’espacer la realisation de scanners complets plus irradiants, l’utilisation d’un protocole avec seulement des coupes expirees permettrait un diagnostic tomodensitometrique de qualite tout en reduisant l’irradiation chez les enfants atteints de mucoviscidose.
- Published
- 2020
- Full Text
- View/download PDF
4. Delayed diagnosis of foreign body aspiration in children
- Author
-
A. Rance, M. Mittaine, M. Michelet, A. Martin Blondel, and G. Labouret
- Subjects
Airway Obstruction ,Male ,Delayed Diagnosis ,Pediatrics, Perinatology and Child Health ,Bronchoscopy ,Humans ,Infant ,Bronchi ,Female ,Child ,Foreign Bodies ,Bronchiectasis ,Retrospective Studies - Abstract
To assess the diagnostic and therapeutic difficulties as well as the long-term complications of prolonged endobronchial foreign body retention.Between January 2000 and May 2021, 794 patients with suspected foreign body aspiration (FBA) were hospitalized in our department. A total of 12 patients with a delayed diagnosis of over 1 month were included. FBAs were confirmed by flexible or rigid endoscopy. A retrospective analysis of medical records was performed.Six male patients and six female patients were hospitalized due to prolonged FBA. The average age was 6.90 years (range: 1-13 years). The average duration of the foreign body retention was 2.60 years (2 months to 9 years). A choking event was found in eight cases. Coughing and wheezing were the main symptoms and signs. A misdiagnosis of asthma was made for five patients. Two atypical clinical presentations led to diagnosis of endobronchial foreign body, unilateral pleurisy, and hemoptysis. We report one case of an occult foreign body externalized spontaneously through a pneumo-pleuro-cutaneous fistula. The most common clinical and radiological findings were of pneumonia and atelectasis. Computed tomography showed localized bronchiectasis in three patients. FBAs were removed with a rigid bronchoscope in eight cases. Other extractions were carried out with a flexible endoscope. The foreign bodies were most frequently of vegetable origin, such as seeds and peanuts. A granulation tissue was observed in seven cases. Bronchial stenosis and bronchiectasis are the most common late complications. Only one patient needed a surgical intervention.FBA should always be considered in the differential diagnosis of chronic or recurrent respiratory diseases, even in the absence of a previous choking event. Clinical and radiological findings should be carefully evaluated for a possible FBA. Delay in diagnosis and treatment of FBA should be avoided in order to prevent complications. Open surgery may be required when lung abscess has occurred.
- Published
- 2021
5. Dépistage néonatal de la mucoviscidose en France : aspects pratiques et perspectives
- Author
-
C. Llerena, M. Mittaine, Marie-Pierre Audrézet, N. Remus, T. Nguyen Khoa, N. Wizla, F. Huet, C. Raynal, J. Brouard, Anne Munck, D. Cheillan, E. Girodon, M. Rota, Isabelle Sermet-Gaudelus, S. Bui, M Roussey, and E. Deneuville
- Subjects
03 medical and health sciences ,0302 clinical medicine ,030228 respiratory system ,030225 pediatrics - Abstract
Resume Le depistage neonatal (DNN) de la mucoviscidose, grâce a une prise en charge multidisciplinaire tres precoce des nourrissons, est optimal en termes de pronostic pour les patients. Depuis 20 ans, il a connu une expansion internationale spectaculaire. Les performances du DNN national francais realise depuis 2002 sont en accord avec les standards europeens pour la valeur predictive positive (0,31 pour un minimum de 0,30) et la specificite (0,95 pour un minimum de 0,95) ; nous soulignons le nombre tres faible de cas non conclus, un pourcentage tres eleve de test de la sueur realises (95,5 %) et d’identification des mutations (96,6 %), un ratio de cas de mucoviscidose par rapport aux cas de diagnostic incertain de 6,3:1, ainsi qu’une strategie efficace pour reperer les faux negatifs. Une nouvelle organisation du DNN francais vient de se mettre en place, il est capital de maintenir l’efficacite du processus, du nouveau-ne en maternite jusqu’au diagnostic dans des centres de reference ou de competences de la mucoviscidose avec un recueil exhaustif des donnees et leur validation. Par ailleurs, une proposition de changement d’algorithme introduisant le dosage du polypeptide d’activation pancreatique est soumise aux nouvelles instances du DNN. L’annonce d’un diagnostic positif reste difficile et peu standardisee, si bien qu’une plateforme de simulation est en cours de mise en place. Nous detaillons ici les bonnes pratiques et les difficultes de realisation du test de la sueur, avec les seuils de chlorures recemment redefinis, ainsi que les modalites du conseil genetique.
- Published
- 2019
- Full Text
- View/download PDF
6. Increased Fecal Calprotectin is Associated with Worse Gastrointestinal Symptoms and Quality of Life Scores in Children with Cystic Fibrosis
- Author
-
Fabien Beaufils, Michael Fayon, Raphaël Enaud, Stéphanie Bui, Laurence Delhaes, Thierry Lamireau, Emmanuel Mas, H. Clouzeau, François Galode, M. Mittaine, Martin Addra, Centre de recherche Cardio-Thoracique de Bordeaux [Bordeaux] (CRCTB), Université Bordeaux Segalen - Bordeaux 2-CHU Bordeaux [Bordeaux]-Institut National de la Santé et de la Recherche Médicale (INSERM), Aquitaine’s Care and Research organisation for inflammatory and Immune-Mediated diseases [CHU Bordeaux] (FHU ACRONIM), CHU Bordeaux [Bordeaux], CIC Bordeaux, Université Bordeaux Segalen - Bordeaux 2-Institut National de la Santé et de la Recherche Médicale (INSERM), Institut de Recherche en Santé Digestive (IRSD ), Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Ecole Nationale Vétérinaire de Toulouse (ENVT), Institut National Polytechnique (Toulouse) (Toulouse INP), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Institut National Polytechnique (Toulouse) (Toulouse INP), Université Fédérale Toulouse Midi-Pyrénées-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE), CHU Toulouse [Toulouse], Bordeaux population health (BPH), Université de Bordeaux (UB)-Institut de Santé Publique, d'Épidémiologie et de Développement (ISPED)-Institut National de la Santé et de la Recherche Médicale (INSERM), Admin, Oskar, and Centre Hospitalier Universitaire de Toulouse (CHU Toulouse)
- Subjects
medicine.medical_specialty ,Nausea ,lcsh:Medicine ,Gastroenterology ,Cystic fibrosis ,[SDV.MHEP.PSR]Life Sciences [q-bio]/Human health and pathology/Pulmonology and respiratory tract ,Article ,03 medical and health sciences ,0302 clinical medicine ,Bloating ,[SDV.MHEP.PED] Life Sciences [q-bio]/Human health and pathology/Pediatrics ,Quality of life ,030225 pediatrics ,Internal medicine ,gas ,intestinal inflammation ,Medicine ,[SDV.MHEP.PED]Life Sciences [q-bio]/Human health and pathology/Pediatrics ,business.industry ,lcsh:R ,[SDV.MHEP.HEG]Life Sciences [q-bio]/Human health and pathology/Hépatology and Gastroenterology ,General Medicine ,pancreatic insufficiency ,medicine.disease ,nausea ,[SDV.MHEP.HEG] Life Sciences [q-bio]/Human health and pathology/Hépatology and Gastroenterology ,humanities ,3. Good health ,[SDV.SPEE] Life Sciences [q-bio]/Santé publique et épidémiologie ,Vomiting ,Biomarker (medicine) ,[SDV.MHEP.PSR] Life Sciences [q-bio]/Human health and pathology/Pulmonology and respiratory tract ,030211 gastroenterology & hepatology ,[SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie ,reflux ,Calprotectin ,medicine.symptom ,business ,Dysbiosis - Abstract
In cystic fibrosis (CF), cystic fibrosis transmembrane regulator (CFTR) dysfunction leads to digestive disorders that promote intestinal inflammation and dysbiosis enhancing gastrointestinal symptoms. In pancreatic insufficiency CF patients, both intestinal inflammation and dysbiosis, are associated with an increase in the fecal calprotectin (FC) level. However, associations between the FC level, gastrointestinal symptoms, and quality of life (QoL) remain poorly studied. We aimed to assess such associations in pancreatic insufficiency CF children. The FC level was measured in pancreatic insufficiency CF children&rsquo, s stool samples. Children and their parents completed two questionnaires: The Gastrointestinal Symptoms Scales 3.0-PedsQLTM and the Quality of Life Pediatric Inventory 4.0-PedsQLTM. Lower scores indicated worse symptomatology or QoL. Thirty-seven CF children were included. A FC level above 250 µ, g/g was associated with worse gastrointestinal symptoms and QoL scores. The FC level was inversely correlated with several gastrointestinal scores assessed by children (i.e., Total, &ldquo, Heart Burn Reflux&rdquo, &ldquo, Nausea and Vomiting&rdquo, and &ldquo, Gas and Bloating&rdquo, ). Several QoL scores were correlated with gastrointestinal scores. The FC level was weakly associated with clinical parameters. Some gastrointestinal and QoL scores were related to disease severity associated parameters. In CF, the FC level, biomarker previously related to intestinal inflammation and dysbiosis, was associated with worse digestive symptoms and QoL scores.
- Published
- 2020
- Full Text
- View/download PDF
7. Management of initial colonisations with Burkholderia species in France, with retrospective analysis in five cystic fibrosis Centres: a pilot study
- Author
-
Christine Segonds, Hélène Guet-Revillet, Vianney Gruzelle, Julie Macey, Raphaël Chiron, Stéphanie Bui, M. Mittaine, Marlène Murris-Espin, and Marine Michelet
- Subjects
0301 basic medicine ,Pulmonary and Respiratory Medicine ,Adult ,Male ,medicine.medical_specialty ,Vital capacity ,Burkholderia gladioli ,Adolescent ,Cystic Fibrosis ,medicine.drug_class ,030106 microbiology ,Antibiotics ,Pilot Projects ,Cystic fibrosis ,03 medical and health sciences ,Young Adult ,0302 clinical medicine ,Internal medicine ,Forced Expiratory Volume ,Secondary Prevention ,Medicine ,Humans ,Prospective cohort study ,Child ,BCC ,Respiratory Tract Infections ,Eradication ,Retrospective Studies ,lcsh:RC705-779 ,biology ,business.industry ,Burkholderia cepacia complex ,Burkholderia Infections ,lcsh:Diseases of the respiratory system ,biology.organism_classification ,medicine.disease ,Anti-Bacterial Agents ,Burkholderia ,Treatment Outcome ,030228 respiratory system ,Sputum ,Female ,France ,medicine.symptom ,business ,Research Article - Abstract
Background Whereas Burkholderia infections are recognized to impair prognosis in cystic fibrosis (CF) patients, there is no recommendation to date for early eradication therapy. The aim of our study was to analyse the current management of initial colonisations with Burkholderia cepacia complex (BCC) or B. gladioli in French CF Centres and its impact on bacterial clearance and clinical outcome. Methods We performed a retrospective review of the primary colonisations (PC), defined as newly positive sputum cultures, observed between 2010 and 2018 in five CF Centres. Treatment regimens, microbiological and clinical data were collected. Results Seventeen patients (14 with BCC, and 3 with B. gladioli) were included. Eradication therapy, using heterogeneous combinations of intravenous, oral or nebulised antibiotics, was attempted in 11 patients. Six out of the 11 treated patients, and 4 out of the 6 untreated patients cleared the bacterium. Though not statistically significant, higher forced expiratory volume in 1 second and forced vital capacity at PC and consistency of treatment with in vitro antibiotic susceptibility tended to be associated with eradication. The management of PC was shown to be heterogeneous, thus impairing the statistical power of our study. Large prospective studies are needed to define whom to treat, when, and how. Conclusions Pending these studies, we propose, due to possible spontaneous clearance, to check the presence of Burkholderia 1 month after PC before starting antibiotics, at least in the milder cases, and to evaluate a combination of intravenous beta-lactam + oral or intravenous fluoroquinolone + inhaled aminoglycoside.
- Published
- 2020
8. Management of initial colonisations with Burkholderia species in France, a retrospective analysis in five Cystic Fibrosis Centres
- Author
-
Stéphanie Bui, Vianney Gruzelle, Marine Michelet, Hélène Guet-Revillet, Julie Macey, Raphaël Chiron, Christine Segonds, M. Mittaine, and Marlène Murris-Espin
- Subjects
medicine.medical_specialty ,Internal medicine ,medicine ,Burkholderia species ,Retrospective analysis ,Biology ,medicine.disease ,Cystic fibrosis - Abstract
Whereas Burkholderia infections are recognized to impair prognosis in cystic fibrosis (CF) patients, there is no recommendation to date for early eradication therapy. The aim of our study was to analyse the current management of initial colonisations with Burkholderia cepacia complex (BCC) or B. gladioli in French CF Centres and its impact on bacterial clearance and clinical outcome. We performed a retrospective review of the primary colonisations (PC) observed between 2010 and 2018 in five CF Centres. Treatment regimens, microbiological and clinical data were collected. Seventeen patients (14 with BCC, and 3 with B. gladioli) were included. Eradication therapy, using heterogeneous combinations of intravenous, oral or nebulised antibiotics, was attempted in 11 patients. Six out of the 11 treated patients, and 4 out of the 6 untreated patients cleared the bacterium. Though not statistically significant, higher FEV1 and FVC at PC and consistency of treatment with in vitro antibiotic susceptibility tended to be associated with eradication. Thus, the management of PC was shown to be heterogeneous, and the statistic power of our study insufficient. Large prospective studies are needed to define who to treat, when, and how. Pending these studies, we propose, due to possible spontaneous clearance, to check the presence of Burkholderia one month after PC before starting antibiotics, at least in the milder cases, and to evaluate a combination of IV beta-lactam + oral or IV fluoroquinolone + inhaled aminoglycoside.
- Published
- 2020
- Full Text
- View/download PDF
9. P154 Population pharmacokinetic (POP-PK) model is useful to optimise tobramycin dosage in cystic fibrosis patients
- Author
-
L. Darnaud, M. Mittaine, P. Gandia, Hélène Guet-Revillet, and M. Murris
- Subjects
Pulmonary and Respiratory Medicine ,education.field_of_study ,medicine.medical_specialty ,business.industry ,Population ,medicine.disease ,Cystic fibrosis ,Gastroenterology ,Pharmacokinetics ,Internal medicine ,Pediatrics, Perinatology and Child Health ,Tobramycin ,medicine ,business ,education ,medicine.drug - Published
- 2020
- Full Text
- View/download PDF
10. [Computed tomography in children with cystic fibrosis: The role of an expiratory protocol]
- Author
-
S, Simon, C, Baunin, J, Vial, E, Mas, L, Roditis, M, Michelet, and M, Mittaine
- Subjects
Male ,Adolescent ,Cystic Fibrosis ,Respiration ,Prognosis ,Radiation Dosage ,Respiratory Function Tests ,Cohort Studies ,Cross-Sectional Studies ,Exhalation ,Child, Preschool ,Occupational Exposure ,Humans ,Female ,Radiography, Thoracic ,Child ,Tomography, X-Ray Computed ,Monitoring, Physiologic ,Retrospective Studies - Abstract
Chest computed tomography (CT) is essential to monitor lung disease in children with cystic fibrosis, but it involves recurrent exposure to ionizing radiation. The aim of this study was to compare the current complete CT protocol (volumetric end-inspiratory plus sequential expiratory acquisition) to a sequential expiratory acquisition protocol alone in terms of image analysis and ionizing radiation dose.Seventy-eight CT scans from 57 children aged 5 to 18 years old were scored on the complete protocol images and on the expiratory sequential images only. Each CT protocol was scored independently, using the Brody scoring system, by two paediatric radiologists.Correlations between the Brody global scores of the two different CT protocols were very good (r=0.90 for both observers), for the bronchiectasis score (r=0.72 and 0.86), mucus plugging score (r=0.87 and 0.83), and expiratory trapped air (r=0.96 and 0.92). Total ionizing radiation dose was reduced, with the measured dose length product (DLP) reduced from 103.31mGy.cm (complete protocol) to 3.06mGy.cm (expiratory protocol) (P0.001).An expiratory chest CT protocol was accurate in diagnosing early signs of CF disease and permitted significant reduction of radiation dose. This protocol would allow spacing out of complete CT scanning with its higher radiation dose and should be considered for the monitoring of lung disease severity in children with CF.
- Published
- 2019
11. EPS1.01 Physiotherapy practice of French cystic fibrosis children changed during lockdown due to COVID-19 pandemic
- Author
-
A. Arrouy, P. Maumus, E. Aversenq, M. Mittaine, C. Lannibois, and P. Milhorat
- Subjects
Pulmonary and Respiratory Medicine ,2019-20 coronavirus outbreak ,medicine.medical_specialty ,Coronavirus disease 2019 (COVID-19) ,business.industry ,Chest physiotherapy ,medicine.disease ,Viral infection ,Cystic fibrosis ,Respiratory status ,Pulmonary function testing ,Pediatrics, Perinatology and Child Health ,Pandemic ,Physical therapy ,medicine ,business - Abstract
Objectives: In France, chest physiotherapy for cystic fibrosis (CF) patients is partly performed by liberal physiotherapists at home or at the professional's office. The first lockdown, due to the COVID-19 pandemic, impaired the possibility to practice liberal physiotherapy. We aimed to describe, in our paediatric CF centre, the changes in physiotherapy and sport practice induced by this lockdown, and to correlate it with respiratory symptoms and pulmonary function evolution. Methods: During the lockdown, 68 CF patients >6 years old and their parents answered a questionnaire on time spent in physiotherapy, with or without a liberal professional, and sport practice before and during lockdown. Respiratory symptoms and FEV1 were collected at the venues before and after the lockdown. Results: This study showed a clear reduction of time spent with a liberal physiotherapist from 73 min/week before lockdown to 30 min/week during lockdown. Time of physiotherapy practised alone or with parents increased from 2 min/week to 26 min/week. Thus, the overall physiotherapy time per week was only slightly reduced from 90 min/week before lockdown to 80 min/week during lockdown. Time spent in sport practice was not significantly decreased on average (233 min/week before lockdown vs 225 min/week during lockdown). The standard deviation of sport practice evolution was large (–8 min ± 225 min), reflecting a wide variation of sport practice changes from one patient to another. No deterioration in respiratory symptoms nor FEV1 was observed. Conclusions: During the lockdown in France, we noted that our patients drastically decreased their time spent with a liberal physiotherapist, without enough counterbalance with auto-drainage or sport pratice increase. Nevertheless, their respiratory status was not impaired, suggesting some other confounding factors, such as prevention from viral infection, time to rest or improvement of other treatment observance.
- Published
- 2021
- Full Text
- View/download PDF
12. P234 Aloe arborescens improves intestinal function and quality of life in 3 children with cystic fibrosis
- Author
-
N. Laborde, C. Lannibois, C. Viard, P. Maumus, Emmanuel Mas, M. Mittaine, and G. Labouret
- Subjects
Pulmonary and Respiratory Medicine ,medicine.medical_specialty ,biology ,business.industry ,medicine.disease ,biology.organism_classification ,Cystic fibrosis ,Gastroenterology ,Quality of life (healthcare) ,Internal medicine ,Pediatrics, Perinatology and Child Health ,medicine ,Aloe arborescens ,business - Published
- 2020
- Full Text
- View/download PDF
13. P258 Do smoking habits of parents of cystic fibrosis children differ from parents of diabetes mellitus type 1 children?
- Author
-
A. Rabeau, A. Arrouy, C. Morin, M. Lafont, M. Mittaine, and M. Michelet
- Subjects
Pulmonary and Respiratory Medicine ,Pediatrics ,medicine.medical_specialty ,business.industry ,Smoking habit ,Diabetes mellitus ,Pediatrics, Perinatology and Child Health ,Medicine ,business ,medicine.disease ,Cystic fibrosis - Published
- 2020
- Full Text
- View/download PDF
14. WS03.4 Lumacaftor/ivacaftor improves the intestinal inflammation in children with cystic fibrosis
- Author
-
M. Fayon, Emmanuel Mas, Thierry Lamireau, M. Mittaine, C. Collet, F. Galode, Stéphanie Bui, Pierre-Régis Burgel, C. Tetard, F. Beaufils, Laurence Delhaes, R. Enaud, and H. Clouzeau
- Subjects
Pulmonary and Respiratory Medicine ,medicine.medical_specialty ,business.industry ,Lumacaftor ,medicine.disease ,Gastroenterology ,Cystic fibrosis ,Ivacaftor ,chemistry.chemical_compound ,chemistry ,Intestinal inflammation ,Internal medicine ,Pediatrics, Perinatology and Child Health ,medicine ,business ,medicine.drug - Published
- 2020
- Full Text
- View/download PDF
15. Bacterial colonization status of cystic fibrosis children's toothbrushes: A pilot study
- Author
-
A. Genevois, Emmanuel Mas, M. Mittaine, Christine Roques, F. Brémont, Laurent Cavalié, Laurent Maubisson, Chrsitine Segonds, Centre National de la Recherche Scientifique - CNRS (FRANCE), Institut National Polytechnique de Toulouse - INPT (FRANCE), Université Toulouse III - Paul Sabatier - UT3 (FRANCE), Université Toulouse 1 Capitole - UT1 (FRANCE), Centre Hospitalier Universitaire de Toulouse - CHU Toulouse (FRANCE), Institut Fédératif de Biologie - IFB (FRANCE), Université de Tours (FRANCE), Laboratoire de Génie Chimique - LGC (Toulouse, France), Toulouse School of Management Research - TSMR (Toulouse, France), Institut National Polytechnique de Toulouse - Toulouse INP (FRANCE), CHU Toulouse [Toulouse], Laboratoire de génie chimique [ancien site de Basso-Cambo] (LGC), Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Centre National de la Recherche Scientifique (CNRS)-Institut National Polytechnique (Toulouse) (Toulouse INP), Université Fédérale Toulouse Midi-Pyrénées, Institut Fédératif de Biologie de Purpan, Université Francois Rabelais [Tours], Institut d'Administration des Entreprises (IAE) - Tours, Val de Loire Recherche en Management (VALLOREM), Université d'Orléans (UO)-Université de Tours, and Université d'Orléans (UO)-Université de Tours (UT)
- Subjects
Male ,Staphylococcus aureus ,medicine.medical_specialty ,Adolescent ,Cystic Fibrosis ,Population ,Dentistry ,Pilot Projects ,medicine.disease_cause ,Cystic fibrosis ,Dental Devices, Home Care ,law.invention ,03 medical and health sciences ,[CHIM.GENI]Chemical Sciences/Chemical engineering ,0302 clinical medicine ,law ,Internal medicine ,medicine ,Humans ,Génie chimique ,[SPI.GPROC]Engineering Sciences [physics]/Chemical and Process Engineering ,Colonization ,Child ,Génie des procédés ,education ,Lung ,education.field_of_study ,Pseudomonas aeruginosa ,business.industry ,Toothbrushes ,Sputum ,030206 dentistry ,medicine.disease ,3. Good health ,medicine.anatomical_structure ,030228 respiratory system ,Pediatrics, Perinatology and Child Health ,Equipment Contamination ,Female ,Toothbrush ,medicine.symptom ,business - Abstract
International audience; Pseudomonas aeruginosa and Staphylococcus aureus toothbrush contamination in cystic fibrosis (CF) is unknown. This pilot study aimed to determine their prevalence and the potential involvement of toothbrushes in pulmonary infection. Methods. Toothbrush bacteriological analysis for children aged 8–18 years was conducted on 27 CF patients, 15 healthy siblings, and 15 healthy children from the general population. Results : S. aureus was detected on 22% of the patients’ toothbrushes, and 13% of healthy children's toothbrushes and P. aeruginosa on 15% of patients’ toothbrushes and 0–13% of healthy children's toothbrushes. There was no statistical correlation between pulmonary colonization and toothbrush contamination. P. aeruginosa genotyping showed two identical clones on the patients’ toothbrushes and in their sputum, and between one patient's sputum and his sibling's toothbrush. Conclusion : S. aureus and P. aeruginosa can colonize CF patients’ toothbrushes. The impact on pulmonary colonization remains unknown. Toothbrush decontamination methods need to consider these bacteria in CF patients.
- Published
- 2015
- Full Text
- View/download PDF
16. Fermeture percutanée d’une fistule artério-veineuse pulmonaire responsable d’une hypoxémie chronique chez une enfant de 7 ans
- Author
-
Yves Dulac, S. Hascoet, François Heitz, M. Mittaine, R. Amadieu, Philippe Acar, and L. Barnet
- Subjects
Pediatrics, Perinatology and Child Health - Abstract
Resume Les fistules arterio-veineuses pulmonaires sont des vaisseaux anormaux reliant l’artere aux veines pulmonaires. Elles entrainent un shunt extracardiaque droite-gauche a l’origine d’une hypoxemie refractaire a l’oxygenotherapie. Nous rapportons le cas d’une fillette de 7 ans presentant une volumineuse fistule arterio-veineuse (FAV) pulmonaire avec une hypoxemie refractaire decouverte a l’occasion d’une anesthesie generale pour adenoidectomie. Cette FAV a ete diagnostiquee par l’angioscanner thoracique. Une occlusion percutanee a ete realisee en deux temps au cours d’un catheterisme cardiaque interventionnel. Ce fait clinique illustre les circonstances de decouverte, la demarche diagnostique face a une hypoxemie refractaire de l’enfant et les avantages et inconvenients de la fermeture percutanee de FAV pulmonaire.
- Published
- 2015
- Full Text
- View/download PDF
17. P147 Burkholderia primo-infection treatment in cystic fibrosis patients: report of 17 cases
- Author
-
Julie Macey, Christine Segonds, M. Murris, M. Mittaine, V. Gruzelle, Stéphanie Bui, Hélène Guet-Revillet, Raphaël Chiron, M. Michelet, and L. Roditis
- Subjects
Pulmonary and Respiratory Medicine ,Pathology ,medicine.medical_specialty ,Burkholderia ,biology ,business.industry ,Pediatrics, Perinatology and Child Health ,Medicine ,business ,biology.organism_classification ,medicine.disease ,Cystic fibrosis - Published
- 2019
- Full Text
- View/download PDF
18. Étude transversale de l’âge à la ménarche et de la mise en place des premiers cycles chez des femmes suivies pour mucoviscidose
- Author
-
P. Ernoult, A. Tournier, M. Muris, M. Mittaine, Audrey Cartault, M. Bournez, F. Bremont, and Catherine Pienkowski
- Subjects
Endocrinology ,Endocrinology, Diabetes and Metabolism ,General Medicine - Abstract
Objectifs Decrire l’âge de menarche et le deroulement pubertaire des filles atteintes de mucoviscidose. Patients, methodes Il s’agit d’une etude transversale, multicentrique, chez 164 jeunes filles de plus de 8 ans suivies pour mucoviscidose dans 7 CRCM. L’âge median aux premieres regles a ete estime par la methode de Kaplan-Meier chez 164 filles dont 97 reglees. Nous avons compare certains parametres lies a la maladie entre le groupe des filles avec une puberte retardee (PR) et le groupe avec une puberte normale (PN). Resultats L’âge median aux premieres regles est estime a 13 ans [11–21 ans]. Ces resultats correspondent a ceux observes dans la population generale, mais la distribution des âges montre une proportion plus importante de pubertes retardees (17,3 % versus 5 %, p Conclusion Il s’agit de la plus grande cohorte de suivi pubertaire de patientes atteintes de mucoviscidose montrant un âge de menarche comparable a la population generale. Les precedentes etudes sont anciennes et decrivaient un retard de menarche de 2 ans. Cependant, il faut rester vigilant sur le depistage des retards pubertaires qui demeurent plus frequents que dans la population generale.
- Published
- 2017
- Full Text
- View/download PDF
19. P215 Age at menarche in girls with cystic fibrosis
- Author
-
C. Munzer, A. Tournier, C. Vaysse, M. Bournez, C. Pienkowski, A. Cartault, M. Murris, M. Mittaine, F. Brémont, and M. Tauber
- Subjects
Pulmonary and Respiratory Medicine ,Pediatrics ,medicine.medical_specialty ,business.industry ,Pediatrics, Perinatology and Child Health ,medicine ,Menarche ,medicine.disease ,business ,Cystic fibrosis - Published
- 2018
- Full Text
- View/download PDF
20. P025 Lumacaftor/ivacaftor in real life for Phe508del homozygous, adolescents with severe and normal lung function
- Author
-
Stéphanie Bui, F. Galode, François Bremont, M. Fayon, C. Collet, and M. Mittaine
- Subjects
Pulmonary and Respiratory Medicine ,Pediatrics ,medicine.medical_specialty ,business.industry ,Lumacaftor ,Normal lung function ,medicine.disease ,Cystic fibrosis ,Ivacaftor ,chemistry.chemical_compound ,chemistry ,Pediatrics, Perinatology and Child Health ,In real life ,Medicine ,business ,medicine.drug - Published
- 2018
- Full Text
- View/download PDF
21. WS06.2 Interest of sequential expiratory chest computed tomography in monitoring lung disease of children with cystic fibrosis
- Author
-
C. Baunin, S. Simon, J. Vial, M. Mittaine, S. Combelles, L. Gauthier, and François Bremont
- Subjects
Pulmonary and Respiratory Medicine ,medicine.medical_specialty ,medicine.diagnostic_test ,Lung disease ,business.industry ,Pediatrics, Perinatology and Child Health ,medicine ,Computed tomography ,Radiology ,medicine.disease ,business ,Cystic fibrosis - Published
- 2018
- Full Text
- View/download PDF
22. Nitric oxide and carbon monoxide lung transfer in patients with advanced liver cirrhosis
- Author
-
Hervé Guénard, Jean-Marie Péron, Nassim Kamar, Lionel Rostaing, Bruno Degano, Gilles Garcia, Daniel Rivière, Jacques Rami, Christophe Bureau, and M. Mittaine
- Subjects
Liver Cirrhosis ,Male ,medicine.medical_specialty ,Pathology ,Cirrhosis ,Physiology ,Nitric Oxide ,Gastroenterology ,Nitric oxide ,chemistry.chemical_compound ,DLCO ,Physiology (medical) ,Internal medicine ,medicine ,Humans ,Respiratory system ,Lung ,Carbon Monoxide ,business.industry ,Middle Aged ,respiratory system ,medicine.disease ,respiratory tract diseases ,Oxygen tension ,medicine.anatomical_structure ,chemistry ,Spirometry ,Breathing ,Pulmonary Diffusing Capacity ,Female ,business ,Carbon monoxide - Abstract
In advanced cirrhosis, decreased lung transfer for carbon monoxide (TLCO) and increased alveolar-arterial oxygen tension difference (PA-aO2≥15 mmHg while breathing ambient air) are frequently detected. Pulmonary membrane diffusion capacity for CO (DmCO) and pulmonary capillary blood volume (Vcap) can be derived from the simultaneous measurement of TLCO and lung transfer for nitric oxide (TLNO). Measurements of single-breath TLNO and TLCO were performed in 49 cirrhotic patients with advanced liver cirrhosis and in 35 healthy controls to derive Vcap, DmCO, and TLNO:TLCO ratio. Twenty-five patients had increased PA-aO2, of whom 11 had hepatopulmonary syndrome (HPS). Compared with controls, non-HPS patients with normal PA-aO2had a significant ∼10% decrease in TLCO, DmCO, and Vcap but similar TLNO:TLCO ratios. Compared with non-HPS patients with normal PA-aO2, non-HPS patients with increased PA-aO2had lower Vcap and higher TLNO:TLCO ratio but similar DmCO. HPS patients had lower Vcap and higher TLNO:TLCO ratios than both subgroups of non-HPS patients. In cirrhotic patients, TLNO:TLCO ratios correlated positively, and TLCO (percentage of the predicted value) and Vcap (percentage of the predicted value) correlated negatively with PA-aO2( r2= 0.25, P = 0.0003, r2= 0.48, P < 0.0001 and r2= 0.57, P < 0.0001, respectively). We concluded that, in cirrhotic patients, lower TLCO and increased PA-aO2are associated with lower Vcap. In addition, high TLNO:TLCO ratios in patients with increased PA-aO2suggest a decreased thickness of the capillary blood layer in these patients.
- Published
- 2009
- Full Text
- View/download PDF
23. Nitric oxide production by the alveolar compartment of the lungs in cirrhotic patients
- Author
-
Bertrand Suc, M. Mittaine, Nassim Kamar, Jacques Rami, Daniel Rivière, Bruno Degano, Lionel Rostaing, and P. Herve
- Subjects
Adult ,Male ,Pulmonary and Respiratory Medicine ,Cardiac Catheterization ,medicine.medical_specialty ,Cirrhosis ,Cardiac index ,Nitric Oxide ,Gastroenterology ,Nitric oxide ,chemistry.chemical_compound ,Internal medicine ,medicine ,Humans ,Hepatopulmonary syndrome ,Lung ,business.industry ,Liver Diseases ,Hemodynamics ,Arteries ,Oxygenation ,Middle Aged ,respiratory system ,medicine.disease ,Fibrosis ,Oxygen ,Pulmonary Alveoli ,medicine.anatomical_structure ,chemistry ,Case-Control Studies ,Circulatory system ,Vascular resistance ,Female ,business - Abstract
In cirrhotic patients, alveolar nitric oxide (NO) concentration is increased. This may be secondary to increased output of NO produced by the alveoli (V'(A,NO)) and/or to decreased lung transfer factor of NO. In advanced liver cirrhosis, NO produced by the alveoli may play a role in abnormalities of pulmonary haemodynamics and gas exchanges. In cirrhotic patients, we aimed to measure V'(A,NO) and to compare V'(A,NO) with pulmonary haemodynamics and gas exchange parameters. Measurements were performed in 22 healthy controls and in 29 cirrhotic patients, of whom eight had hepatopulmonary syndrome. Exhaled NO concentrations were measured at multiple expiratory flow rates to derive alveolar NO concentration. V'(A,NO) was the product of alveolar NO concentration by single breath lung transfer factor for NO. V'(A,NO) was increased in patients (median (range) 260 (177-341) nL x min(-1)) compared with controls (79 (60-90), p0.0001). Alveolar-arterial oxygen tension difference failed to correlate with V'(A,NO). However, cardiac index correlated positively and systemic vascular resistance correlated negatively with V'(A,NO) (r = 0.56, p = 0.001 and r = -0.52, p = 0.004, respectively). In cirrhotic patients, NO was produced in excess by the alveolar compartment of the lungs. Alveolar NO production was associated with hyperdynamic circulatory syndrome but not with arterial oxygenation impairment.
- Published
- 2009
- Full Text
- View/download PDF
24. Atopie, rhinite allergique et sport
- Author
-
D. Riviere, M. Mittaine, Alain Didier, L. Tetu, and F. Pillard
- Subjects
Gynecology ,medicine.medical_specialty ,business.industry ,Physical activity ,Immunology and Allergy ,Medicine ,business - Abstract
Resume Introduction La frequence elevee des manifestations respiratoires d’allure asthmatique a ete clairement demontree chez les athletes de haut niveau. Les donnees chez les sportifs occasionnels et sur les autres manifestations atopiques (rhinite allergique, sensibilisations aux allergenes) sont plus contradictoires. Methodes Une association entre le temps d’entrainement et la presence d’une rhinite allergique ou de critere d’atopie a ete recherchee chez 153 sujets de niveaux sportifs differents. Dans un sous-groupe de sujets s’entrainant intensement (au moins dix heures hebdomadaires), l’influence du mode de pratique (exterieur/interieur, endurance/resistance) a ete analysee. Resultats Aucune association n’a ete retrouvee entre le temps de pratique sportive et l’existence de rhinite allergique ou d’atopie. Chez les sportifs s’entrainant intensivement, la pratique en milieu interieur etait significativement associee a la rhinite allergique. Parmi les sportifs s’entrainant intensivement, 32,1 % etaient porteurs de rhinite allergique. Soixante-cinq pour cent des rhinites allergiques responsables d’un inconfort nasal n’etaient pas traitees. Conclusions Le temps de pratique sportive n’est pas directement lie a la presence de rhinite allergique ou d’atopie. Le lieu de pratique sportive semble jouer un role. La rhinite allergique reste frequente et negligee chez le sportif.
- Published
- 2009
- Full Text
- View/download PDF
25. Paecilomyces lilacinus et variotii dans la mucoviscidose
- Author
-
Emmanuel Mas, Sylvain Blanchon, L. Tetu, A. Berry, M. Mittaine, G. Labouret, Alain Didier, X. Iriart, François Bremont, S. Cassaing, M. Murris, P. Vermersch, J. Fillaux, Pharmacochimie et Biologie pour le Développement (PHARMA-DEV), Institut de Recherche pour le Développement (IRD)-Institut de Chimie de Toulouse (ICT-FR 2599), Institut National Polytechnique (Toulouse) (Toulouse INP), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Centre National de la Recherche Scientifique (CNRS)-Institut de Recherche pour le Développement (IRD)-Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées-Institut de Chimie du CNRS (INC)-Institut National Polytechnique (Toulouse) (Toulouse INP), Université Fédérale Toulouse Midi-Pyrénées-Institut de Chimie du CNRS (INC), Institut de Recherche pour le Développement (IRD)-Institut de Chimie de Toulouse (ICT), Institut de Recherche pour le Développement (IRD)-Université Toulouse III - Paul Sabatier (UT3), Université de Toulouse (UT)-Université de Toulouse (UT)-Institut de Chimie du CNRS (INC)-Centre National de la Recherche Scientifique (CNRS)-Institut National Polytechnique (Toulouse) (Toulouse INP), Université de Toulouse (UT)-Institut de Recherche pour le Développement (IRD)-Université Toulouse III - Paul Sabatier (UT3), and Université de Toulouse (UT)
- Subjects
Pulmonary and Respiratory Medicine ,03 medical and health sciences ,0302 clinical medicine ,030228 respiratory system ,[SDV]Life Sciences [q-bio] ,Paecilomyces lilacinus ,030212 general & internal medicine ,variotii ,mucoviscidose ,ComputingMilieux_MISCELLANEOUS ,3. Good health - Abstract
Objectif Paecilomyces lilacinus (PL) et variotii (PV) sont des champignons opportunistes emergents, non etudies dans la mucoviscidose. Methode Etude retrospective aux CRCM enfants et adultes de Toulouse sur les donnees informatisees du 01/01/2008 au 01/09/2014. Sont etudiees les caracteristiques des patients au 1 er isolement de Paecilomyces (P) dans l’expectoration, et leur evolutivite : VEMS et IMC en % de la norme, a 1 an et 2 ans avant et apres, et le type de colonisation bronchique chronique, intermittente ou ponctuelle. Resultat Sur cette periode sont realisees 3337 analyses microbiologiques de l’expectoration chez 98 enfants (de plus de 5 ans) et 164 adultes ; 39 (1,1 %) sont positifs pour P. Vingt patients ont au moins une fois du P : 2 colonisations chroniques (PL), 4 intermittentes (PL) et 14 ponctuelles (12 PL, 2 PV). Au 1 er isolement, l’âge median est de 13 ans (9 a 36), le VEMS median de 82 % (28 a 112) et le BMI median de 94 % (79 a 113). Tous sont colonises a Pseudomonas aeruginosa , 17 a S. aureus , et 14 a Aspergillus . La charge therapeutique semble elevee : l’annee precedente, 11 (55 %) ont de l’itraconazole, 13 une corticotherapie (12 inhalees, 1 par voie orale), 14 de l’azithromycine, 10 une antibiotherapie inhalee, 10 des ATB IV. Le profil des patients selon le type de colonisation ne differe pas, hormis l’itraconazole prescrit chez 100 % des patients chroniques et intermittents (vs 35 % chez les colonises ponctuels). P ne semble pas influencer l’evolutivite : VEMS et BMI restent stables. Conclusion P semble peu pathogene, mais survient chez des patients avec une charge therapeutique elevee. La sensibilite diminuee de P a l’itraconazole peut evoquer une pression de selection par ce traitement.
- Published
- 2015
26. Diagnostic value of bronchoscopy, CT and transbronchial biopsies in diffuse pulmonary lymphangiomatosis: case report and review of the literature
- Author
-
M. Mittaine, Alain Didier, Valérie Chabbert, J.P. Bolduc, Marcel Dahan, L. El Hajj, F. Joffre, Julien Mazieres, and Isabelle Rouquette
- Subjects
Male ,medicine.medical_specialty ,Pathology ,Lung Neoplasms ,Bronchi ,Diagnosis, Differential ,Sarcoidosis, Pulmonary ,Bronchoscopy ,Predictive Value of Tests ,Biopsy ,medicine ,Fiber Optic Technology ,Humans ,Lymphangiectasis ,Radiology, Nuclear Medicine and imaging ,Tuberculosis, Pulmonary ,Lymphangiomatosis ,Lung ,Lymphangioma ,medicine.diagnostic_test ,business.industry ,Biopsy, Needle ,General Medicine ,Middle Aged ,medicine.disease ,Lymphatic system ,medicine.anatomical_structure ,Histopathology ,Radiology ,Sarcoidosis ,Tomography, X-Ray Computed ,business - Abstract
The authors present the case of a 48-year-old man with diffuse pulmonary lymphangiomatosis. This rare lymphatic disorder is characterized by proliferation of anastomosing lymphatic vessels varying in size. Clinical presentation and imaging findings are highly suggestive. Bronchoscopic examination of this patient showed, for the first time to our knowledge, vesicles disseminated throughout the bronchial tree. Histopathological examinations are necessary to differentiate lymphangiomatosis from lymphangiectasis. The diagnosis can be made by transbronchial biopsy without performing open lung biopsy which was, until now, considered necessary for diagnosis.
- Published
- 2005
- Full Text
- View/download PDF
27. Mucoviscidose : revue bibliographique de l’année 2015
- Author
-
L. Bassinet and M. Mittaine
- Subjects
Pulmonary and Respiratory Medicine ,03 medical and health sciences ,0302 clinical medicine ,030228 respiratory system ,business.industry ,Medicine ,030212 general & internal medicine ,business - Published
- 2016
- Full Text
- View/download PDF
28. Évolution nutritionnelle au cours de la première année de vie des enfants dépistés pour la mucoviscidose
- Author
-
Emmanuel Mas, C. Camps-Guiran, Sylvain Blanchon, M. Mittaine, M. Nau, F. Brémont, and G. Labouret
- Subjects
Pediatrics, Perinatology and Child Health - Abstract
But Evaluer l’impact du depistage neonatal de la mucoviscidose sur l’evolution nutritionnelle precoce. Methode Etude retrospective monocentrique realisee du 1/10/02 au 31/12/12 qui a evalue au moment du diagnostic et vers un an les parametres nutritionnels cliniques et biologiques. L’analyse a ete faite en 3 sous-groupes en fonction de la valeur de l’elastase fecale initiale : suffisant (SP), intermediaire et insuffisant pancreatique (IP), respectivement elastase > 200, 15–200 et t de Student non apparie pour les variables continues, exprimees en moyenne ± DS, et en un test de Chi 2 pour les variables categorielles, exprimees en pourcentage. Resultats Cinquante-deux enfants ont ete diagnostiques durant cette periode dont 43 par depistage neonatal (7 pathologies chirurgicales neonatales et 2 faux negatifs). Ils etaient repartis en 8 SP (17 %), 10 intermediaires (21 %) et 28 IP (59 %). Lors de l’annonce, a 37 ± 14 jours, le poids etait significativement plus bas dans le groupe IP (−1,13 ± 1,18 DS, p p Au niveau biologique, les valeurs au diagnostic de l’albumine et du zinc serique etaient plus basses dans le groupe IP. Au cours du suivi, a ete notee une augmentation des taux d’acide eicosapentaenoique et une diminution du taux d’acide docosahexaenoique quel que soit le statut pancreatique. Concernant les vitamines liposolubles, la principale difference concernait la vitamine E dont le taux etait significativement plus bas au diagnostic dans le groupe IP vs. SP, respectivement de 5,8 ± 4,2 vs. 11,1 ± 3,4 mg/L ( p = 0,01). Conclusion Le depistage neonatal de la mucoviscidose a permis une correction a un an des anomalies nutritionnelles presentes au moment du diagnostic. Toutefois, une attention particuliere doit etre portee aux nourrissons ayant une fonction pancreatique « intermediaire », dont le statut nutritionnel a un an etait moins bon.
- Published
- 2016
- Full Text
- View/download PDF
29. 85 What is bacterial colonisation of cystic fibrosis children toothbrushes?
- Author
-
Laurent Maubisson, Chrsitine Segonds, A. Genevois, Christine Roques, Laurent Cavalié, M. Mittaine, and F. Brémont
- Subjects
Pulmonary and Respiratory Medicine ,Pseudomonas aeruginosa ,business.industry ,Pulmonary infection ,medicine.disease_cause ,medicine.disease ,Cystic fibrosis ,Microbiology ,Bacterial colonization ,Staphylococcus aureus ,Pediatrics, Perinatology and Child Health ,medicine ,Pediatrics, Perinatology, and Child Health ,business - Abstract
Pseudomonas aeruginosa or Staphylococcus aureus toothbrushes contamination in cystic fibrosis (CF) patients is unknown. The objective of this pilot study was to determine prevalence of those germs on toothbrushes of CF and healthy children, and define if toothbrushes may be involved in pulmonary infection.
- Published
- 2014
- Full Text
- View/download PDF
30. [Embolization of pulmonary arteriovenous malformation causing hypoxemia in a 7-year-old child]
- Author
-
L, Barnet, M, Mittaine, F, Heitz, R, Amadieu, P, Acar, Y, Dulac, and S, Hascoet
- Subjects
Pulmonary Veins ,Arteriovenous Fistula ,Humans ,Female ,Pulmonary Artery ,Child ,Hypoxia ,Embolization, Therapeutic - Abstract
Pulmonary arteriovenous fistulas are abnormal vessels joining the right pulmonary artery to the pulmonary veins. They lead to an extracardiac right-to-left shunt with refractory hypoxemia. We report the case of a 7-year-old girl with a large pulmonary arteriovenous fistula discovered with refractory hypoxemia diagnosed during general anesthesia for adenoidectomy. Radio-opacity was observed on the upper lobe of the right lung. The diagnosis was made using thoracic angiotomography. The proximal arterial vessel arose from the lobar pulmonary artery. The fistula had developed in the entire right upper lobe and drained into two veins flowing into the right superior pulmonary artery. Given the marked hypoxemia, the potential risks of pulmonary hemorrhage and pulmonary infection, an occlusion of the fistula was indicated. After discussion between surgeons and interventional cardiologists, catheterization was indicated. The occlusion of the fistula was successful at the second attempt after release of a vascular plug in the main proximal vessel. This case illustrates the clinical circumstances of diagnosis of arteriovenous fistula, the diagnostic algorithm for refractory hypoxemia and the therapeutic options, with discussion of the benefits and drawbacks of a catheterization procedure.
- Published
- 2014
31. Anaphylaxie au sarrasin par voie inhalée
- Author
-
Alain Didier, Raphaël Culerrier, Camille Sordet, Annick Barre, Pierre Rougé, and M. Mittaine
- Subjects
Anesthesiology and Pain Medicine ,Immunology and Allergy - Abstract
Resume Une jeune fille presente un tableau de choc anaphylactique, apres etre entree dans une creperie, mais… avant toute consommation alimentaire ! Le bilan allergologique montre une sensibilisation aux acariens et au sarrasin. L’histoire clinique et le bilan allergologique font suspecter les allergenes de sarrasin aeroportes dans la genese de cette reaction anaphylactique. En immuno-empreinte, le serum de la patiente reagit contre une albumine 2S, allergene majeur du sarrasin, mais aussi contre une globuline 13S, dont le role dans la reaction par voie aeroportee reste a determiner. Le sarrasin est repandu en Asie dans l’alimentation et pour usages domestiques. En Occident, sa consommation revient a la mode. Notre cas clinique est un nouvel exemple de reaction severe a cet allergene, deja decrit comme responsable de reactions graves par voie inhalee comme par voie ingeree.
- Published
- 2008
- Full Text
- View/download PDF
32. Antioxidant Potential is Correlated to ω6 / ω3 Ratio and Brasfield Score in Cystic Fibrosis Children
- Author
-
Julien Mancini, Jean Gaudart, Jésus Garcia, J.-L. Rittié, Emmanuel Mas, M. Mittaine, F. Brémont, Sylvie Caspar-Bauguil, Alexandre Fabre, Gaudart, Jean, Lab Physiol Anim, Univ Ouagadougou, UFR SVT, Institut des Maladies Métaboliques et Cardiovasculaires (I2MC), Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Institut National de la Santé et de la Recherche Médicale (INSERM), Aix Marseille Université (AMU), Sciences Economiques et Sociales de la Santé & Traitement de l'Information Médicale (SESSTIM - U912 INSERM - Aix Marseille Univ - IRD), Institut de Recherche pour le Développement (IRD)-Aix Marseille Université (AMU)-Institut National de la Santé et de la Recherche Médicale (INSERM), Institut Paoli-Calmettes, Fédération nationale des Centres de lutte contre le Cancer (FNCLCC), Pneumologie Allergologie Pédiatrique et Mucoviscidose, Centre hospitalier Félix-Guyon [Saint-Denis, La Réunion], Service Pneumologie et allergologie pédiatrique [CHU Toulouse], Pôle Enfants [CHU Toulouse], Centre Hospitalier Universitaire de Toulouse (CHU Toulouse)-Centre Hospitalier Universitaire de Toulouse (CHU Toulouse), Institut de Recherche pour le Développement (IRD)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Aix Marseille Université (AMU), Pédiatrie - Pneumologie, Allergologie, Hôpital des Enfants, CHU Toulouse [Toulouse]-CHU Toulouse [Toulouse], and Université de Toulouse (UT)-Université de Toulouse (UT)-Institut National de la Santé et de la Recherche Médicale (INSERM)
- Subjects
Male ,[MATH.MATH-PR] Mathematics [math]/Probability [math.PR] ,Erythrocytes ,Antioxidant ,Multivariate analysis ,Cystic Fibrosis ,Exacerbation ,Endocrinology, Diabetes and Metabolism ,medicine.medical_treatment ,Medicine (miscellaneous) ,medicine.disease_cause ,Gastroenterology ,Cystic fibrosis ,Antioxidants ,Pulmonary function testing ,0302 clinical medicine ,[STAT.AP] Statistics [stat]/Applications [stat.AP] ,[MATH.MATH-ST]Mathematics [math]/Statistics [math.ST] ,[SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseases ,030212 general & internal medicine ,Child ,[MATH.MATH-ST] Mathematics [math]/Statistics [math.ST] ,[SDV.MHEP.ME] Life Sciences [q-bio]/Human health and pathology/Emerging diseases ,[STAT.AP]Statistics [stat]/Applications [stat.AP] ,[SDV.MHEP.ME]Life Sciences [q-bio]/Human health and pathology/Emerging diseases ,Nutrition and Dietetics ,[STAT.ME] Statistics [stat]/Methodology [stat.ME] ,Anthropometry ,Chemistry ,General Medicine ,Micronutrient ,Respiratory Function Tests ,[SDV.MHEP.MI] Life Sciences [q-bio]/Human health and pathology/Infectious diseases ,Biomarker (medicine) ,Female ,[STAT.ME]Statistics [stat]/Methodology [stat.ME] ,[SDV.MP.PAR] Life Sciences [q-bio]/Microbiology and Parasitology/Parasitology ,medicine.medical_specialty ,Adolescent ,[MATH.MATH-DS]Mathematics [math]/Dynamical Systems [math.DS] ,Nutritional Status ,[MATH.MATH-DS] Mathematics [math]/Dynamical Systems [math.DS] ,03 medical and health sciences ,Sex Factors ,Fatty Acids, Omega-6 ,Internal medicine ,Fatty Acids, Omega-3 ,medicine ,Humans ,[SDV.EE.SANT] Life Sciences [q-bio]/Ecology, environment/Health ,[SDV.MP.PAR]Life Sciences [q-bio]/Microbiology and Parasitology/Parasitology ,Retrospective Studies ,[SDV.EE.SANT]Life Sciences [q-bio]/Ecology, environment/Health ,medicine.disease ,[SDE.ES]Environmental Sciences/Environmental and Society ,[MATH.MATH-PR]Mathematics [math]/Probability [math.PR] ,Oxidative Stress ,030228 respiratory system ,[SDV.SPEE] Life Sciences [q-bio]/Santé publique et épidémiologie ,Immunology ,[SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie ,[SDE.ES] Environmental Sciences/Environmental and Society ,Biomarkers ,Oxidative stress - Abstract
Objectives: Oxidative stress is associated with the condition of cystic fibrosis (CF), but no guidelines exist for its assessment or treatment. Our aim was to evaluate a test that measures the blood antioxidant capability in CF children. Methods: This antioxidant capability was assessed by the Kit Radicaux Libres (KRL) test in 44 CF children (24 boys). We recorded also anthropometric measures, pulmonary function, CF severity scores, and plasma nutritional and inflammatory parameters (proteins, vitamins, erythrocyte fatty acids, and micronutrients). We performed univariate and multivariate analyses with linear regression models. Results: The mean age at the first KRL assessment was 12.2 ± 3.8 years. Factors that correlated with decreased antioxidant capacity were mostly related to the severity of pulmonary disease [ forced expiratory volume at 1 second (FEV1), acute exacerbation, and congestion. In multivariate analysis, the correlation between Brasfield score and erythrocyte antioxidant potential remained significant (β = - 0.611, p < 0.001). Among nutritional factors, the ω6/ω3 ratio was significantly correlated to erythrocyte antioxidant potential (β = - 1.213, p = 0.01). Conclusion: The blood antioxidant capability, measured by the KRL test, appears to be an interesting biomarker to evaluate oxidative stress in CF. This study suggests that the ω6/ω3 ratio should be regarded as a nutritional marker in antioxidant management in CF children.
- Published
- 2013
- Full Text
- View/download PDF
33. 352 Minocycline in CF patients: beware of myopericarditis!
- Author
-
Emmanuel Mas, M. Mittaine, J.-L. Rittié, F. Brémont, and Y. Dulac
- Subjects
Pulmonary and Respiratory Medicine ,medicine.medical_specialty ,biology ,business.industry ,Omalizumab ,Immunoglobulin E ,medicine.disease ,Aspergillosis ,Cystic fibrosis ,Internal medicine ,Pediatrics, Perinatology and Child Health ,biology.protein ,medicine ,Pediatrics, Perinatology, and Child Health ,Allergic bronchopulmonary aspergillosis ,Complication ,business ,Depression (differential diagnoses) ,medicine.drug ,Myopericarditis - Abstract
Background: Allergic bronchopulmonary aspergillosis (ABPA) is a common complication among patients with CF that produces significant respiratory morbidity. Standard therapy for ABPA includes systemic corticosteroids for a prolonged period of time with potentially severe side effects and use of antifungal agents. Omalizumab is a humanized monoclonal antibody directed against IgE that prevents its binding to receptors on effector cells. It has been shown to be effective in improving asthma control in patients with a strong allergic component. Recently, sporadic reports of omalizumab use against ABPA have been reported. Methods: We present our long term experience of omalizumab in three children with CF and ABPA who were steroid dependent. Results: Five (3.4%) out of 148 children and adolescents with CF followed in our Unit over a seven year period, developed ABPA (75% females, mean age at start of therapy 14.3 years). Omalizumab was given to 3 of them (2 males, mean age 17.1 years, mean FEV1 35%). All three were already experiencing significant side effects from chronic steroid therapy (invasive aspergillosis, diabetes mellitus, depression, relapse of ABPA and severe osteoporosis) and received regular antifugal therapy. Omalizumab treatment was given for a period of 12−18 months. Oral steroids were gradually stopped. Omalizumab resulted in significant improvement of respiratory symptoms and lung function (mean FEV1 52%, p: 0.01). Conclusion: According to our results in a small number of patients, omalizumab has a significant potential as a strategy to control ABPA in steroid dependent patients. However, more studies are needed to confirm these findings.
- Published
- 2012
- Full Text
- View/download PDF
34. [Cystic fibrosis: transition from child to adult]
- Author
-
F, Brémont, M, Mittaine, A, Martin-Blondel, J-L, Rittié, E, Mas, L, Tetu, and M, Murris
- Subjects
Young Adult ,Adolescent ,Cystic Fibrosis ,Age Factors ,Humans ,Child ,Pediatrics ,Referral and Consultation - Published
- 2009
35. La mucoviscidose : transition de l’enfant à l’adulte
- Author
-
M. Mittaine, F. Brémont, A. Martin-Blondel, M. Murris, L. Tetu, Emmanuel Mas, and J.-L. Rittié
- Subjects
business.industry ,Pediatrics, Perinatology and Child Health ,Medicine ,business - Published
- 2009
- Full Text
- View/download PDF
36. Réponse à la « Lettre à la rédaction » des docteurs M. Mairesse et C. Ledent
- Author
-
A. Didier and M. Mittaine
- Subjects
Anesthesiology and Pain Medicine ,Immunology and Allergy - Published
- 2008
- Full Text
- View/download PDF
37. 193 Habitual physical activity evaluation in CF children: accelerometry feasibility and comparison with questionnaires
- Author
-
L. Leseux, M. Mittaine, F. Brémont, Emmanuel Mas, F. Pillard, and J.-L. Rittié
- Subjects
Pulmonary and Respiratory Medicine ,education.field_of_study ,medicine.medical_specialty ,Medical staff ,business.industry ,Population ,Physical activity ,Medical evaluation ,Accelerometer ,Clinical trial ,Pediatrics, Perinatology and Child Health ,Evaluation methods ,Physical therapy ,Medicine ,Pediatrics, Perinatology, and Child Health ,Objective evaluation ,education ,business - Abstract
Introduction: Physical activity is beneficial for cystic fibrosis (CF) patients. This induces to stimulate their habitual physical activity (HAP) from childhood. Thus, for HAP evaluation, we need methods that are simple, reliable, objective and well accepted by the patients. Accelerometry is one of the possibilities for evaluating HAP. We studied its feasibility, acceptability and correlation with other HAP evaluation methods in a population of paediatric CF patients. Methods: 34 CF patients, aged between 9 and 18 years, were proposed to wear accelerometers. The reasons for not wearing the accelerometer were evaluated. A correlation was measured between the data produced by accelerometry, the answers to HAES and Veerschuur questionnaires, and evaluations by medical staff. Results: – 14 children out of 34 (41%) did not wear the accelerometer, 5 of them simply refused it; 6 children (17%) have worn the accelerometer less than 5 days. Finally, 14 recordings were interpretable, i.e. 41% of the 34 children to whom the measurement was proposed. – The answers to the questionnaires appeared not to be correlated to the accelerometry data. But there was a good correlation of 62.1% (p = 0.017) between the data obtained by accelerometry and the medical evaluation. Conclusion: The feasibility of the HAP evaluation by accelerometry in a pediatric CF population is only around 40%. Therefore it cannot be used in every-day clinical practice. However, in clinical trials, the objective evaluation by accelerometry should be preferred because of the discrepancies observed with answers to standardized questionnaires on physical activity.
- Published
- 2012
- Full Text
- View/download PDF
38. La production de monoxyde d’azote par le compartiment alvéolaire est augmentée chez les patients cirrhotiques
- Author
-
Lionel Rostaing, Jacques Rami, Bruno Degano, P. Herve, M. Mittaine, and D. Riviere
- Subjects
Pulmonary and Respiratory Medicine - Abstract
Introduction : Chez les patients cirrhotiques, la concentration alveolaire de monoxyde d’azote (CA, NO) est augmentee mais pas le debit bronchique de NO (J’maxbr,NO), Le monoxyde d’azote (NO) pourrait etre un facteur clef dans l’hemodynamique pulmonaire et les anomalies des echanges gazeux de ces patients. Methodes : Les objectifs de notre travail ont ete, dans une population de patients cirrhotiques, (1) de mesurer la production de NO par le compartiment alveolaire pulmonaire (V’A,NO) et (2) de comparer V’A,NO avec l’hemodynamique pulmonaire et la difference alveolo-arterielle en oxygene (PA-a,O2). Les concentrations de NO exhale ont ete mesurees par la methode des debits multiples afin de calculer CA,NO. La mesure du transfert pulmonaire du monoxyde d’azote (TL,NO) a ete mesuree par une technique « en apnee », et V’A,NO a ete calculee comme le produit de CA,NO par TL,NO Un catheterisme droit a ete pratique dans un sous-groupe de patients. Resultats : Le NO exhale et le TL,NO ont ete mesures chez 26 sujets normaux et chez 40 patients cirrhotiques, dont 9 porteurs d’un syndrome hepato-pulmonaire. On retrouvait une augmentation de V’A,NO chez les patients compares au groupe controle (408 ± 160 vs 238 ± 126 nLmin-1 respectivement, p
- Published
- 2008
- Full Text
- View/download PDF
39. Le volume sanguin capillaire pulmonaire est diminué dans la cirrhose sévère
- Author
-
J.-M. Péron, Jacques Rami, D. Riviere, L Alric, Bruno Degano, Lionel Rostaing, and M. Mittaine
- Subjects
Pulmonary and Respiratory Medicine - Abstract
Introduction : Une diminution du transfert pulmonaire du monoxyde de carbone (TL,CO) et une augmentation de la difference alveolo-arterielle en oxygene (PA–a,O 2 ) sont deux anomalies frequentes chez les patients atteints de cirrhose severe. L’equation de Roughton et Forster permet de calculer la capacite de diffusion membranaire du CO (Dm,CO) et le volume sanguin capillaire pulmonaire (Vcap) a partir de la mesure simultanee de TL,CO et du transfert pulmonaire du monoxyde d’azote (TL,NO). L’objectif de ce travail est de determiner quelle composante de TL,CO (Vcap et/ou Dm,CO) est associee a la baisse de TL,CO et a l’augmentation de (PA–a,O 2 ). Methodes : La mesure simultanee de TL,CO et TL,NO a ete realisee par une technique « en apnee » chez une serie de 49 patients cirrhotiques en attente de transplantation hepatique. La PA-a,O 2 a ete calculee a partir de la mesure des gaz du sang arteriels preleves en air ambiant. Les correlations entre PA–a,O 2 d’une part, et TL,CO, Vcap, Dm,CO et le rapport TL,NO/TL,CO d’autre part ont ete recherchees. Resultats : 25 patients presentaient une hypoxemie (PA-a,O 2 > 15mmHg), et 11 patients presentaient un syndrome hepato-pulmonaire (SHP). Les patients ayant un SHP avaient un TL,CO et un Vcap (exprimes en pourcentage de leur valeur theorique) plus bas (63 ± 18 % vs 89 ± 15 %, p vs 90 ± 16 %, p vs 4,3 ± 0,4, p = 0,005) que les patients n’ayant pas de SHP. En revanche, le Dm,CO des patients ayant un SHP n’etait pas significativement different du Dm,CO des patients sans SHP (76 ± 27 % vs 87 ± 25, p = 0,22). Pour l’ensemble des patients, on retrouvait une correlation negative entre TL,CO et PA–a,O 2 (r2 = 0,48, p 2 (r2 = 0,25, p 2 (r2 = 0,57, p Conclusion : Les anomalies d’oxygenation du sang arteriel rencontrees chez les patients cirrhotiques sont associees a une diminution de la perfusion d’alveoles ventiles. Ce resultat est compatible (1) avec l’existence d’une obstruction arteriolaire touchant certains territoires pulmonaires et (2) des territoires pulmonaires a bas rapport ventilation/perfusion realisant un effet shunt voire, dans le cas du SHP, un shunt anatomique.
- Published
- 2008
- Full Text
- View/download PDF
40. 485 Atopie et rhinite allergique : le sport est-il un facteur de risque ?
- Author
-
D. Riviere, M. Mittaine, Alain Didier, L. Tetu, and F. Pillard
- Subjects
Pulmonary and Respiratory Medicine - Published
- 2007
- Full Text
- View/download PDF
41. The expanded French compassionate programme for elexacaftor-tezacaftor-ivacaftor use in people with cystic fibrosis without a F508del CFTR variant: a real-world study.
- Author
-
Burgel PR, Sermet-Gaudelus I, Girodon E, Durieu I, Houdouin V, Audousset C, Macey J, Grenet D, Porzio M, Murris-Espin M, Reix P, Baravalle M, Belleguic C, Mely L, Verhille J, Weiss L, Reynaud-Gaubert M, Mittaine M, Hamidfar R, Ramel S, Cosson L, Douvry B, Danner-Boucher I, Foucaud P, Roy C, Burnet E, Raynal C, Audrezet MP, Da Silva J, and Martin C
- Subjects
- Humans, Male, Female, France, Adult, Adolescent, Child, Young Adult, Pyrroles therapeutic use, Chloride Channel Agonists therapeutic use, Treatment Outcome, Quinolones therapeutic use, Pyrrolidines, Quinolines, Cystic Fibrosis drug therapy, Cystic Fibrosis genetics, Benzodioxoles therapeutic use, Aminophenols therapeutic use, Cystic Fibrosis Transmembrane Conductance Regulator genetics, Indoles therapeutic use, Drug Combinations, Compassionate Use Trials, Pyrazoles therapeutic use, Pyridines therapeutic use
- Abstract
Background: Elexacaftor-tezacaftor-ivacaftor has been approved in Europe for people with cystic fibrosis with at least one F508del CFTR variant. Additionally, it is approved by the US Food and Drug Administration (FDA) for people with cystic fibrosis with at least one of 177 rare variants. The aims of this study were to describe the clinical response to elexacaftor-tezacaftor-ivacaftor for people with cystic fibrosis without a F508del CFTR variant in France and to determine CFTR variant responsiveness to elexacaftor-tezacaftor-ivacaftor based on the observed clinical response., Methods: The French compassionate programme expanded access to elexacaftor-tezacaftor-ivacaftor to people with cystic fibrosis, aged 6 years and older, without a F508del variant, excluding those with two variants previously characterised as non-responsive. Participants at France's 47 cystic fibrosis centres were given a 4-6 week trial of elexacaftor-tezacaftor-ivacaftor and response was determined by a centralised committee based on evolution of clinical data, lung function, and sweat chloride concentration. Responsiveness of individual CFTR variants was derived from observed clinical responses., Findings: The first compassionnate programme was launched on May 19, 2022; by March 8, 2024, 516 people with cystic fibrosis had been identified for inclusion in this real-word study: 37 were not included due to the presence of two variants previously characterised as non-responsive to elexacaftor-tezacaftor-ivacaftor, and 479 (229 females [48%] and 250 males [52%]) received elexacaftor-tezacaftor-ivacaftor for 4-6 weeks. Among 443 participants who received no CFTR modulator before elexacaftor-tezacaftor-ivacaftor, 83 had at least one FDA-approved variant, of whom 81 (98%) were responders and continued elexacaftor-tezacaftor-ivacaftor; in responders, mean absolute change in sweat chloride was -44·5 mmol/L (95% CI -39·1 to -49·8) and percentage of predicted FEV
1 (ppFEV1 ) was 11·1 percentage points (95% CI 8·4 to 13·7; both comparisons p<0·0001). Among 360 participants with no FDA-approved variant and no previous CFTR modulator, 177 (49%) were responders; in responders, mean absolute change in sweat chloride was -20·5 mmol/L (-17·2 to -23·8) and ppFEV1 was 13·2 percentage points (11·4 to 15·0; both comparisons p<0·0001). Among 36 participants who were receiving ivacaftor before elexacaftor-tezacaftor-ivacaftor, 32 (89%) continued elexacaftor-tezacaftor-ivacaftor. Of 251 individual CFTR variants, 64 (28 FDA-approved) were classified as responsive or possibly responsive to elexacaftor-tezacaftor-ivacaftor, and 123 (two FDA-approved) as non-responsive or possibly non-responsive to elexacaftor-tezacaftor-ivacaftor., Interpretation: In France, over half of the population with cystic fibrosis without a F508del variant responded to elexacaftor-tezacaftor-ivacaftor, with most responders having no FDA-approved variant. The treatment period was relatively short and further research is warranted to describe the long-term safety and effectiveness of elexacaftor-tezacaftor-ivacaftor in this population., Funding: Association Vaincre la Mucoviscidose, Société Française de la Mucoviscidose, and Filière Maladies Rares MUCO-CFTR., Competing Interests: Declaration of interests P-RB declares consulting fees from AstraZeneca, Chiesi, GSK, Insmed, MSD, Sanofi, Vertex, Viatris, and Zambon, outside of the submitted work. IS-G declares grants and consulting fees from Vertex, outside of the submitted work. ID declares support for attending meetings from Mylan and Zambon. CA declares consulting fees from Vertex and Viatris and support for attending meetings from SOS Oxygène, Viatris, and Zambon. DG declares support for attending meetings from Zambon. MM-E declares fees for report testimony from Vertex. MM declares consulting fees from Vertex. BD declares fees for participation on a data safety and monitoring board from Vertex. CR reports grants from Vaincre la Mucoviscidose and unpaid participation on the leadership of the French newborn screening programme and the French Rare Diseases Network. CM declares consulting fees from AstraZeneca, Boehringer Ingelheim, Chiesi, and GSK, and support for attending meetings from Boehringer Ingelheim and Chiesi. All other authors declare no competing interests., (Copyright © 2024 Elsevier Ltd. All rights reserved, including those for text and data mining, AI training, and similar technologies.)- Published
- 2024
- Full Text
- View/download PDF
42. What is the future of children and adolescents with severe asthma treated with biological therapy?
- Author
-
Ladoux C, Guilleminault L, Michelet M, and Mittaine M
- Published
- 2024
- Full Text
- View/download PDF
43. Lumacaftor/Ivacaftor Population Pharmacokinetics in Pediatric Patients with Cystic Fibrosis: A First Step Toward Personalized Therapy.
- Author
-
Bouazza N, Urien S, Foissac F, Choupeaux L, Lui G, Froelicher Bournaud L, Rouillon S, Zheng Y, Bardin E, Stremler N, Bessaci K, Bihouee T, Coirier-Duet E, Marguet C, Deneuville E, Laurans M, Reix P, Gerardin M, Mittaine M, Epaud R, Thumerelle C, Weiss L, Berthaud R, Semeraro M, Treluyer JM, Benaboud S, and Sermet-Gaudelus I
- Subjects
- Humans, Child, Cystic Fibrosis Transmembrane Conductance Regulator genetics, Cystic Fibrosis Transmembrane Conductance Regulator therapeutic use, Drug Combinations, Aminophenols therapeutic use, Aminopyridines therapeutic use, Forced Expiratory Volume, Cystic Fibrosis drug therapy, Cystic Fibrosis genetics, Quinolones, Benzodioxoles
- Abstract
Background: A major breakthrough in cystic fibrosis (CF) therapy was achievedAQ1 with CFTR modulators. The lumacaftor/ivacaftor combination is indicated for the treatment of CF in pediatric patients above 6 years old. Pharmacokinetic (PK) studies of lumacaftor/ivacaftor in these vulnerable pediatric populations are AQ2crucial to optimize treatment protocols., Objectives and Methods: The objectives of this study were to describe the population PK (PPK) of lumacaftor and ivacaftor in children with CF, and to identify factors associated with interindividual variability. The association between drug exposure and clinical response was also investigated., Results: A total of 75 children were included in this PPK study, with 191 concentrations available for each compound and known metabolites (lumacaftor, ivacaftor, ivacaftor-M1, and ivacaftor-M6). PPK analysis was performed using Monolix software. A large interindividual variability was observed. The main sources of interpatient variability identified were patient bodyweight and hepatic function (aspartate aminotransferase). Forced expiratory volume in the first second (FEV1) was statistically associated with the level of exposure to ivacaftor after 48 weeks of treatment., Conclusions: This study is the first analysis of lumacaftor/ivacaftor PPK in children with CF. These data suggest that dose adjustment is required after identifying variability factors to optimize efficacy. The use of therapeutic drug monitoring as a basis for dose adjustment in children with CF may be useful., (© 2024. The Author(s), under exclusive licence to Springer Nature Switzerland AG.)
- Published
- 2024
- Full Text
- View/download PDF
44. Exploration of the relationship between cumulative exposure to tobramycin and ototoxicity in patients with cystic fibrosis.
- Author
-
Madaule J, Valenzuela F, Mittaine M, Gallois Y, Baladi B, Murris M, Calmels MN, Concordet D, and Gandia P
- Subjects
- Humans, Adult, Tobramycin adverse effects, Retrospective Studies, Anti-Bacterial Agents adverse effects, Cystic Fibrosis complications, Cystic Fibrosis drug therapy, Ototoxicity, Hearing Loss chemically induced, Hearing Loss diagnosis, Hearing Loss epidemiology
- Abstract
Background: Aminoglycosides (AGs), such as tobramycin, are essential antibiotics in the management of pulmonary infections in patients with cystic fibrosis (CF). They induce ototoxicity without the relationship being clearly described in the literature. Our aim is to propose a mathematical and statistical model describing the relationship between the estimated cumulative exposure (Area Under the Curve, AUC) to tobramycin and ototoxicity with audiogram interpretation in young patients with CF., Methods: Cumulative AUCs were estimated for each course of tobramycin, for the 106 individuals with CF (between 4 and 22 years of age) enrolled in this retrospective study (35 who had received IV tobramycin, 71 controls). Mean hearing loss was calculated for each audiogram and a statistical model was developed to predict hearing loss., Results: The model confirms a significant relationship between cumulative tobramycin exposure and changes in hearing acuity: Meanhearingloss=2.7+(3×10
-5 )×AUC_tobramycin+individual_susceptibility However, the ototoxic effect is not clinically perceptible (mean hearing loss: 3.8 dB). The impact of AUC on hearing loss is minor in these subjects who received a limited number of courses of tobramycin (median: 5 courses)., Conclusion: A significant relationship between cumulative exposure to tobramycin and ototoxicity was demonstrated. Individual treatment susceptibility should not be overlooked. As ototoxicity is not clinically perceptible in the study subjects, hearing tests should be continued during adulthood to provide individualized medical guidance and to obtain a lifetime analysis of the relationship between exposure and hearing loss., Competing Interests: Declaration of Competing Interests The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2023. Published by Elsevier B.V.)- Published
- 2023
- Full Text
- View/download PDF
45. Higher levels of Pseudomonas aeruginosa LasB elastase expression are associated with early-stage infection in cystic fibrosis patients.
- Author
-
Llanos A, Achard P, Bousquet J, Lozano C, Zalacain M, Sable C, Revillet H, Murris M, Mittaine M, Lemonnier M, and Everett M
- Subjects
- Humans, Pseudomonas aeruginosa genetics, Cluster Analysis, Pancreatic Elastase, Cystic Fibrosis complications, Coinfection
- Abstract
Pseudomonas aeruginosa is a common pathogen in cystic fibrosis (CF) patients and a major contributor to progressive lung damage. P. aeruginosa elastase (LasB), a key virulence factor, has been identified as a potential target for anti-virulence therapy. Here, we sought to differentiate the P. aeruginosa isolates from early versus established stages of infection in CF patients and to determine if LasB was associated with either stage. The lasB gene was amplified from 255 P. aeruginosa clinical isolates from 70 CF patients from the Toulouse region (France). Nine LasB variants were identified and 69% of the isolates produced detectable levels of LasB activity. Hierarchical clustering using experimental and clinical data distinguished two classes of isolates, designated as 'Early' and 'Established' infection. Multivariate analysis revealed that the isolates from the Early infection class show higher LasB activity, fast growth, tobramycin susceptibility, non-mucoid, pigmented colonies and wild-type lasR genotype. These traits were associated with younger patients with polymicrobial infections and high pFEV
1 . Our findings show a correlation between elevated LasB activity in P. aeruginosa isolates and early-stage infection in CF patients. Hence, it is this patient group, prior to the onset of chronic disease, that may benefit most from novel therapies targeting LasB., (© 2023. Springer Nature Limited.)- Published
- 2023
- Full Text
- View/download PDF
46. Moving the Dial on Airway Inflammation in Response to Trikafta in Adolescents with Cystic Fibrosis.
- Author
-
Lepissier A, Bonnel AS, Wizla N, Weiss L, Mittaine M, Bessaci K, Kerem E, Houdouin V, Reix P, Marguet C, and Sermet-Gaudelus I
- Subjects
- Adolescent, Humans, Respiratory System, Aminophenols, Inflammation, Cystic Fibrosis Transmembrane Conductance Regulator, Cystic Fibrosis
- Published
- 2023
- Full Text
- View/download PDF
47. [Transition from pediatric to adult care in chronic respiratory diseases: The cystic fibrosis model].
- Author
-
Mittaine M, Roditis L, and Dupuis M
- Subjects
- Humans, Adult, Child, Referral and Consultation, Patients, Cystic Fibrosis therapy, Transition to Adult Care, Respiration Disorders
- Abstract
Increased life expectancy in cystic fibrosis has made transition from pediatric to adult cystic fibrosis centers a crucial step for patients, their families and caregivers. This transition must be gradual and carefully prepared. A formalized process, early discussion with patients and families about transition, patient's empowerment prior to transfer, and close links between pediatric and adult teams are key points to succeed. Therapeutic education, validated questionnaires, personalized action plans or connected tools can help. Transfer will take place at the appropriate time for each patient, ideally during a period of disease stability, in a progressive manner, with joint or alternating consultations between pediatric and adult cystic fibrosis center teams. Other chronic respiratory diseases with pediatric onset may benefit from similar transition processes., (© 2023 médecine/sciences – Inserm.)
- Published
- 2023
- Full Text
- View/download PDF
48. Delayed diagnosis of foreign body aspiration in children.
- Author
-
Rance A, Mittaine M, Michelet M, Martin Blondel A, and Labouret G
- Subjects
- Bronchi, Bronchoscopy adverse effects, Bronchoscopy methods, Child, Delayed Diagnosis, Female, Humans, Infant, Male, Retrospective Studies, Airway Obstruction etiology, Bronchiectasis, Foreign Bodies complications, Foreign Bodies diagnosis, Foreign Bodies surgery
- Abstract
Aims: To assess the diagnostic and therapeutic difficulties as well as the long-term complications of prolonged endobronchial foreign body retention., Method: Between January 2000 and May 2021, 794 patients with suspected foreign body aspiration (FBA) were hospitalized in our department. A total of 12 patients with a delayed diagnosis of over 1 month were included. FBAs were confirmed by flexible or rigid endoscopy. A retrospective analysis of medical records was performed., Results: Six male patients and six female patients were hospitalized due to prolonged FBA. The average age was 6.90 years (range: 1-13 years). The average duration of the foreign body retention was 2.60 years (2 months to 9 years). A choking event was found in eight cases. Coughing and wheezing were the main symptoms and signs. A misdiagnosis of asthma was made for five patients. Two atypical clinical presentations led to diagnosis of endobronchial foreign body, unilateral pleurisy, and hemoptysis. We report one case of an occult foreign body externalized spontaneously through a pneumo-pleuro-cutaneous fistula. The most common clinical and radiological findings were of pneumonia and atelectasis. Computed tomography showed localized bronchiectasis in three patients. FBAs were removed with a rigid bronchoscope in eight cases. Other extractions were carried out with a flexible endoscope. The foreign bodies were most frequently of vegetable origin, such as seeds and peanuts. A granulation tissue was observed in seven cases. Bronchial stenosis and bronchiectasis are the most common late complications. Only one patient needed a surgical intervention., Conclusions: FBA should always be considered in the differential diagnosis of chronic or recurrent respiratory diseases, even in the absence of a previous choking event. Clinical and radiological findings should be carefully evaluated for a possible FBA. Delay in diagnosis and treatment of FBA should be avoided in order to prevent complications. Open surgery may be required when lung abscess has occurred., Competing Interests: Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Crown Copyright © 2022. Published by Elsevier Masson SAS. All rights reserved.)
- Published
- 2022
- Full Text
- View/download PDF
49. Exposure to inorganic particles in paediatric sarcoidosis: the PEDIASARC study.
- Author
-
Nathan N, Montagne ME, Macchi O, Rosental PA, Chauveau S, Jeny F, Sesé L, Abou Taam R, Brocvielle M, Brouard J, Catinon M, Chapelon-Abric C, Cohen-Aubart F, Delacourt C, Delestrain C, Deschildre A, Dossier A, Epaud R, Haroche J, Houdouin V, Israel-Biet D, Juvin K, Le Jeune S, Lionnet F, Meinzer U, Mittaine M, Nunes H, Mattioni S, Naccache JM, Odièvre MH, Vincent M, Clement A, Valeyre D, and Cavalin C
- Subjects
- Adult, Child, Dust, Environmental Exposure adverse effects, Humans, Occupations, Talc, Occupational Exposure adverse effects, Sarcoidosis
- Abstract
Inorganic antigens may contribute to paediatric sarcoidosis. Thirty-six patients matched with 36 healthy controls as well as a group of 21 sickle-cell disease (SCD) controls answered an environmental questionnaire. Patients' indirect exposure to inorganic particles, through coresidents' occupations, was higher than in healthy and SCD controls (median score: 2.5 (0.5-7) vs 0.5 (0-2), p=0.003 and 1 (0-2), p=0.012, respectively), especially for construction, exposures to metal dust, talc, abrasive reagents and scouring products. Wood or fossil energies heating were also linked to paediatric sarcoidosis. This study supports a link between mineral environmental exposure due to adult coresident occupations and paediatric sarcoidosis., Competing Interests: Competing interests: None declared., (© Author(s) (or their employer(s)) 2022. No commercial re-use. See rights and permissions. Published by BMJ.)
- Published
- 2022
- Full Text
- View/download PDF
50. Long-Term Outcomes in Real Life of Lumacaftor-Ivacaftor Treatment in Adolescents With Cystic Fibrosis.
- Author
-
Bui S, Masson A, Enaud R, Roditis L, Dournes G, Galode F, Collet C, Mas E, Languepin J, Fayon M, Beaufils F, and Mittaine M
- Abstract
Background: The combination of the CFTR corrector lumacaftor (LUM) and potentiator ivacaftor (IVA) has been labeled in France since 2015 for F508del homozygote cystic fibrosis (CF) patients over 12 years. In this real-life study, we aimed (i) to compare the changes in lung function, clinical (e.g., body mass index and pulmonary exacerbations) and radiological parameters, and in sweat chloride concentration before and after initiation of LUM/IVA treatment; (ii) to identify factors associated with response to treatment; and (iii) to assess the tolerance to treatment. Materials and Methods: In this tri-center, non-interventional, and observational cohort study, children (12-18 years old) were assessed prospectively during the 2 years of therapy, and retrospectively during the 2 years preceding treatment. Data collected and analyzed for the study were exclusively extracted from the medical electronic system records of the patients. Results: Forty adolescents aged 12.0-17.4 years at LUM/IVA initiation were included. The lung function decreased significantly during and prior to treatment and increased after LUM/IVA initiation, becoming significant after 2 years of treatment. LUM/IVA significantly improved the BMI Z -score and sweat chloride concentration. By contrast, there was no significant change in exacerbation rates, antibiotic use, or CT scan scores. Age at LUM/IVA initiation was lower in good responders and associated with greater ppFEV1 change during the 2 years of treatment. LUM/IVA was well-tolerated. Conclusion: In F508del homozygote adolescents, real-life long-term LUM/IVA improved the ppFEV1 trajectory, particularly in the youngest patients, nutritional status, and sweat chloride concentration but not exacerbation rates or radiological scores. LUM/IVA was generally well-tolerated and safe., Competing Interests: SB, FG, CC, RE, FB, and MF conducted clinical trials with Vertex pharmacological agents, on behalf of the European Cystic Fibrosis Society-Clinical Trials Network (ECFS-CTN) and within the scope of ECFS-CTN activities. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (Copyright © 2021 Bui, Masson, Enaud, Roditis, Dournes, Galode, Collet, Mas, Languepin, Fayon, Beaufils and Mittaine.)
- Published
- 2021
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.